Literature DB >> 20235259

Structure-based discovery of natural-product-like TNF-α inhibitors.

Daniel Shiu-Hin Chan1, Ho-Man Lee, Fang Yang, Chi-Ming Che, Catherine C L Wong, Ruben Abagyan, Chung-Hang Leung, Dik-Lung Ma.   

Abstract

Small but effective: two natural-product-like inhibitors of tumor necrosis factor α (TNF-α; represented in green in the picture) have been identified using structure-based virtual screening. These compounds represent only the third and fourth examples of direct targeting of TNF-α by a small molecule, and display potency comparable to that of the strongest TNF-α inhibitor reported to date.
Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20235259      PMCID： PMC4162403          DOI： 10.1002/anie.200907360

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  21 in total

Review 1.  Anti-TNF-alpha therapies: the next generation.

Authors:  Michael A Palladino; Frances Rena Bahjat; Emmanuel A Theodorakis; Lyle L Moldawer
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

2.  Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner.

Authors:  Chung-Hang Leung; Susan P Grill; Wing Lam; Wenli Gao; Han-Dong Sun; Yung-Chi Cheng
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

Review 3.  MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.

Authors:  Matthew R Lee; Celia Dominguez
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 4.  Suramin: clinical uses and structure-activity relationships.

Authors:  Ross P McGeary; Andrew J Bennett; Quoc B Tran; Kelly L Cosgrove; Benjamin P Ross
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

Review 5.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

6.  Flexible protein-ligand docking by global energy optimization in internal coordinates.

Authors:  M Totrov; R Abagyan
Journal:  Proteins       Date:  1997

7.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

Authors:  James R Burke; Mark A Pattoli; Kurt R Gregor; Patrick J Brassil; John F MacMaster; Kim W McIntyre; Xiaoxia Yang; Violetta S Iotzova; Wendy Clarke; Joann Strnad; Yuping Qiu; F Christopher Zusi
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

Review 8.  Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.

Authors:  H S Rasmussen; P P McCann
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

9.  Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4.

Authors:  Hao Sun; Garold S Yost
Journal:  Chem Res Toxicol       Date:  2007-12-21       Impact factor: 3.739

10.  LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.

Authors:  Soichi Haraguchi; Noorbibi K Day; Wasu Kamchaisatian; Macarena Beigier-Pompadre; Steffen Stenger; Nutthapong Tangsinmankong; John W Sleasman; Salvatore V Pizzo; George J Cianciolo
Journal:  AIDS Res Ther       Date:  2006-03-31       Impact factor: 2.250
View more
  28 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

2.  Docking to multiple pockets or ligand fields for screening, activity prediction and scaffold hopping.

Authors:  Yu-Chen Chen; Max Totrov; Ruben Abagyan
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

Review 3.  Software and resources for computational medicinal chemistry.

Authors:  Chenzhong Liao; Markus Sitzmann; Angelo Pugliese; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2011-06       Impact factor: 3.808

4.  Structure-based virtual screening identifies a small-molecule inhibitor of the profilin 1-actin interaction.

Authors:  David Gau; Taber Lewis; Lee McDermott; Peter Wipf; David Koes; Partha Roy
Journal:  J Biol Chem       Date:  2017-12-27       Impact factor: 5.157

Review 5.  TNF superfamily protein-protein interactions: feasibility of small- molecule modulation.

Authors:  Yun Song; Peter Buchwald
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Screening bicyclic peptide libraries for protein-protein interaction inhibitors: discovery of a tumor necrosis factor-α antagonist.

Authors:  Wenlong Lian; Punit Upadhyaya; Curran A Rhodes; Yusen Liu; Dehua Pei
Journal:  J Am Chem Soc       Date:  2013-08-01       Impact factor: 15.419

7.  Telmisartan Mitigates TNF-α-Induced Type II Collagen Reduction by Upregulating SOX-9.

Authors:  Xiuying Zhang; Yanfeng Dong; Hanyu Dong; Yanhui Cui; Qing Du; Xiaoli Wang; Lanlan Li; Hongju Zhang
Journal:  ACS Omega       Date:  2021-04-22

8.  Hit identification of IKKβ natural product inhibitor.

Authors:  Chung-Hang Leung; Daniel Shiu-Hin Chan; Ying-Wei Li; Wang-Fun Fong; Dik-Lung Ma
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-07       Impact factor: 2.483

9.  Subunit disassembly and inhibition of TNFα by a semi-synthetic bicyclic peptide.

Authors:  Stefan Luzi; Yasushi Kondo; Elise Bernard; Lukas K J Stadler; Marina Vaysburd; Greg Winter; Philipp Holliger
Journal:  Protein Eng Des Sel       Date:  2015-02       Impact factor: 1.650

10.  Modelling the Transport of Nanoparticles under Blood Flow using an Agent-based Approach.

Authors:  Gavin Fullstone; Jonathan Wood; Mike Holcombe; Giuseppe Battaglia
Journal:  Sci Rep       Date:  2015-06-10       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.